ASSAY and Drug Development Technologies provides access to novel techniques and robust tools that enable critical advances in early-stage screening. This research published in the Journal leads to important therapeutics and platforms for drug discovery and development. This reputable peer-reviewed journal features original papers application-oriented technology reviews, topical issues on novel and burgeoning areas of research, and reports in methodology and technology application.
ASSAY and Drug Development Technologies coverage includes:
Assay design, target development, and high-throughput technologies
Hit to Lead optimization and medicinal chemistry through preclinical candidate selection
Lab automation, sample management, bioinformatics, data mining, virtual screening, and data analysis
Approaches to assays configured for gene families, inherited, and infectious diseases
Assays and strategies for adapting model organisms to drug discovery
The use of stem cells as models of disease
Translation of phenotypic outputs to target identification
Exploration and mechanistic studies of the technical basis for assay and screening artifacts
The Journal also features a dedicated Drug Repurposing, Rescue, and Repositioning (DRRR) section. These special peer-reviewed collections of papers present techniques and tools for finding new uses for approved drugs – particularly for disorders where no animal model, physiologic abnormality, biochemical pathway, or molecular target has been identified.

This DRRR special section features original papers, application-oriented technology reviews, and reports in methodology and technology application to drug repurposing and redevelopment including:
Designing assays and interpreting output to enable alternate drug target identification
Pathway analysis and bioinformatics to identify and exploit drug promiscuity
In silico technologies to identify alternate drug targets
"Big Data" mining and side effect pattern analysis in clinical and healthcare repositories
ASSAY and Drug Development Technologies is under the editorial leadership of Editor-in-Chief Bruce Melancon, PhD, University of Notre Dame; and other leading investigators.The DRRR section is under the leadership of Hermann Mucke, PhD, of Hermann Mucke Pharma Consultancy e.U. View the entire editorial board.

Journal Audience Includes: Drug discovery and assay development scientists, drug delivery and formulation specialists, molecular and behavioral pharmacologists, pharmaceutical and biotechnology researchers, and disease foundation advocates, among others.